S-Adenosylmethionine (SAMe) monotherapy for depression: an 8-week double-blind, randomised, controlled trial

Area of Science:

• Neuroscience
• Psychiatry
• Nutraceutical Research

Background:

• The one carbon cycle is implicated in depression.
• S-adenosylmethionine (SAMe), a nutraceutical, has a theoretical basis for treating depression due to its role in the one carbon cycle.
• Controlled studies are needed to confirm SAMe's efficacy.

Purpose of the Study:

• To evaluate the efficacy of SAMe compared to placebo in unmedicated patients with major depressive disorder (MDD).
• To assess SAMe in patients experiencing mild-to-moderate depressive symptoms.

Main Methods:

• An 8-week, double-blind, randomized controlled trial was conducted.
• 49 unmedicated MDD patients (MADRS score 14-25) received 800 mg/day of SAMe or placebo.
• Biomarkers (one-carbon cycle, BDNF) and SNPs were analyzed as potential moderators.

Main Results:

• A differential reduction in depression symptoms (MADRS) favoring SAMe was observed but not statistically significant (p=0.13).
• A high placebo response rate (53%) was noted.
• Exploratory analysis indicated SAMe effectiveness in participants with milder depression (MADRS ≤ 22, p=0.045).
• Folate levels correlated with symptom improvement in the SAMe group (r=-0.57, p=0.026).

Conclusions:

• This pilot study observed a trend favoring SAMe in reducing depression symptoms, but results did not reach statistical significance.
• SAMe was found to be safe and well-tolerated.
• Further research is warranted to confirm SAMe's efficacy in MDD.